✦ LIBER ✦

Metformin reverses fatty liver disease in obese, leptin-deficient mice

✍ Scribed by Diehl, Anna Mae; Lin, Hui Zhi; Yang, Shi Qi; Chuckaree, Christine; Kuhajda, Francis; Ronnet, Gabriele

Book ID: 109829017
Publisher: Nature Publishing Group
Year: 2000
Tongue: English
Weight: 293 KB
Volume: 6
Category: Article
ISSN: 1078-8956
DOI: 10.1038/79697

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effect of metformin on leptin in obe

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

✍ A. Nar; O. Gedik 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 170 KB

Obesity-related fatty liver is unchanged

✍ György Baffy; Chen-Yu Zhang; Jonathan N. Glickman; Bradford B. Lowell 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB

Liver regeneration in obese mice with fa

Liver regeneration in obese mice with fatty livers: Does the impairment have relevance for other types of fatty liver disease?

✍ Geoffrey C. Farrell; Graham R. Robertson; Isabelle Leclercq; Yves Horsmans 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

TNF-α is not the cause of fatty liver di

TNF-α is not the cause of fatty liver disease in obese diabetic mice

✍ Memon, Riaz A.; Grunfeld, Carl; Feingold, Kenneth R. 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 24 KB

Increased Soluble Leptin Receptor Levels

Increased Soluble Leptin Receptor Levels in Morbidly Obese Patients With Insulin Resistance and Nonalcoholic Fatty Liver Disease

✍ Valentina Medici; MohamedR. Ali; Suk Seo; Christopher A. Aoki; Lorenzo Rossaro; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 132 KB

Abrogation of hepatic ATP-citrate lyase

Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice

✍ Qiong Wang; Lei Jiang; Jue Wang; Shoufeng Li; Yue Yu; Jia You; Rong Zeng; Xiang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 925 KB

Hepatic steatosis is a hallmark of nonalcoholic fatty liver disease (NAFLD) and a key component of obesity-associated metabolic dysfunctions featuring dyslipidemia, insulin resistance, and loss of glycemic control. It has yet to be completely understood how much dysregulated de novo lipogenesis cont